Thursday 3 July 2025
A-TOP Health Biotech unveils JOUVENCE thread lift, expands footprint in global medical aesthetics market
The self-funded medical beauty market has gradually integrated into consumers' daily life, combining the pursuit of outer aesthetics with inner self-confidence, resulting in significant growth in the worldwide medical beauty business.According to a June 2024 survey conducted by the International Society of Aesthetic Plastic Surgery (ISAPS), plastic surgeons worldwide conducted over 15.8 million surgical procedures in 2023, in addition to the 19.1 million non-surgical procedures. Among them, non-surgical skin tightening treatments were ranked fourth in market demand.To capitalize on the substantial business potential within this sector, A-TOP Health Biotech, possessing robust R&D capabilities, introduced its proprietary product "JOUVENCE" to address the shortcomings of current thread materials. The product will soon be submitted for review by the U.S. FDA, with certification expected in the fourth quarter of 2025.As emphasized by Olivia Tseng, founder and chairperson of A-TOP Health Biotech, ongoing advancements in medical aesthetics technology have made major surgical procedures unnecessary for achieving skin firmness. Instead, lifting threads can now be inserted into targeted areas to achieve the desired results. Conventional lifting threads feature a "sharp barb" or "hooked" design that pierces the skin tissue, granting anchorage to facilitate skin lifting; however, this design often causes discomfort, and in some cases, patients may experience excessive inflammation requiring additional surgery.JOUVENCE lifting threads adopt a unique bionic cross-sectional design to avoid the discomfort caused by conventional barbed threads, thereby offering consumers a more comfortable and effective treatment experience.Tseng stated, "JOUVENCE will challenge the traditional paradigm of round thread materials, redefine the technical concept of thread lifting, seamlessly integrate technology and aesthetics to usher in a new era of innovation, and establish itself as a pivotal and trusted brand in the global medical beauty sector."3D Beauty-AI software enables innovation in lifting threadsA-TOP Health Biotech, founded in 2021, is driven by the mission of "Technology and Beauty, Touching the World". The company focuses on developing medical aesthetic and reconstructive surgical materials that are both clinically proven and highly safe, aiming to solve clinical challenges and enhance the quality and efficiency of aesthetic medicine.Its flagship product, JOUVENCE, is a world-first innovation developed using patented non-cutting molding and twisting technology, overcoming the limitations of traditional PDO lifting threads and offering four major advantages. First, its continuous structure provides stable support, reducing the risk of thread slippage and displacement. Second, it eliminates the breakage issues caused by stress concentration in cut threads, resulting in smoother surgical procedures. Third, the absence of sharp structures minimizes the sensation of foreign objects and reduces tissue irritation, significantly lowering inflammation and fibrosis. Fourth, it complies with standardized certification protocols, demonstrating rigorous biocompatibility and excellent product performance.In addition to product innovation, A-TOP Health Biotech addresses clinical pain points by introducing its "3D Beauty-AI Software" to assist physicians. By processing just 15 facial images, the software completes a 3D visual reconstruction, helping non-specialist doctors quickly grasp the key techniques for thread lifting and shortening the learning curve. The AI-generated 3D images also facilitate doctor-patient communication, enhancing transparency and trust in treatment, and further improving the overall medical aesthetic experience.Enhancing worldwide patent deployment: Focus on Taiwan, Thailand, and the USDespite Tseng's extensive practical experience in the medical devices and biotechnology sectors, A-TOP Health Biotech may continue to face multifaceted challenges in areas such as R&D, marketing, and fundraising as the company expands.By joining the Taiwan Tech Arena (TTA), the company gained valuable resources and received comprehensive support from the FlyingVest Accelerator, gradually overcoming key early-stage startup obstacles. The company also successfully secured a spot in the MEDICA Taiwan team organized by Taiwan's National Science and Technology Council (NSTC) in 2024, demonstrating both its technological strength and market potential.In the context of global strategy, Tseng stated that A-TOP Health Biotech will prioritize Thailand, Taiwan, and the US as target markets, combining its JOUVENCE lifting threat technology with 3D Beauty-AI software to provide medical beauty clinics with comprehensive non-surgical skin tightening solutions.A-TOP Health Biotech aspires to establish itself as a globally influential medical aesthetics brand through innovative R&D and international patent strategy, realizing the brand vision of "Technology and Beauty, Touching the World."